{"name":"David Reardon, MD","slug":"david-reardon-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CUE-102","genericName":"CUE-102","slug":"cue-102","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CUE-102","genericName":"CUE-102","slug":"cue-102","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPOXpHcVhWTnNzbjJLT01vcWVBaGh0WVdpRjY2SUpBcEpnOHNuSGt0LWU0eW1WVmtrMnlkdldUcEVmVGx2azN5VU5scnpPSVA1X19KZjdKdVFHUnVPeXJYV05iYmluRG5MR2VsQ0E4MFBYcGV0OFBJMThPa3hrc2cxdTA4ZGhjZkdJZ2RHUjhfNlY5d1RJSjBSSVBnMmtVYXAySU5XMV8zcjhvQTR5QWI1c0JVMjN4UkJ1cGctNFkwVQ?oc=5","date":"2019-01-31","type":"pipeline","source":"Dana-Farber Cancer Institute","summary":"Glioblastoma Survivor is Thriving Seven Years After Diagnosis - Dana-Farber Cancer Institute","headline":"Glioblastoma Survivor is Thriving Seven Years After Diagnosis - Dana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTjZlM253N0pxNmpQalFXemxMMkdPWVVNZl9Sb1p5amlYYUNEZGp6TlFLNHBuQWs1eDNEUkg4N19ld3dwN2NsUTVoTE1jRDJlb1k5T3ctN0hiWE9TVHJ2TjJkbzFmbkJ0elNLNTI5eF9TVXBGcjdERWlPai1rQ0R0ejZSOExVM1ZnZnYxMzBIYjRxUGNMRl90NDhXb1NlaUF0X2xWNUU4QWxpZFJNdHVQb2NfS0ZkY1dsVUswS1Zn?oc=5","date":"2015-08-10","type":"pipeline","source":"ascopost.com","summary":"Glioblastoma: Novel Immunotherapy Approaches Generate Responses and Excitement - ascopost.com","headline":"Glioblastoma: Novel Immunotherapy Approaches Generate Responses and Excitement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVU1mREVvcl8xZkpPRTJ3dUZCNmpQMks4T2gxVW1iMXpKWDNlaDdlaUw0Z3RGTUZ4dXRtaFZpYVFpR0JDTFc2c053Wk15VlpKcHh1clVZNXlmTTlZcWEtVGZDRk5EbjFYZXB4UExhQ0NsZkhtSzllZzF2dERkNGRhUG5UUXZGTkJxLW91VVpydDVrYTdfN25sT2tpcDBHT0JWWF9RYjlqNjNUQjFMb1gzZEtFbk1xNUQ4U0xfR0tSWm8?oc=5","date":"2012-05-22","type":"pipeline","source":"Dana-Farber Cancer Institute","summary":"New developments in brain tumor treatment: Five questions for David Reardon, MD - Dana-Farber Cancer Institute","headline":"New developments in brain tumor treatment: Five questions for David Reardon, MD - Dana","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}